Institutions and their investors appear to be looking to continued growth in clinical research – especially with respect to decentralized clinical trials (DCTs) – which is a healthy trend when a company recently announced significant new funding for the development of a DCT software platform and another significant expansion of testing services are indications of this.
$ 15 million in Series A funding was announced today for Curebase’s ongoing work on its DCT platform and virtual research location capabilities, led by GGV Capital, with the participation of Xfund, Bold Capital and several other institutional funds become. This brings the company’s total to $ 19 million.
Meanwhile, CVS Health announced last week the creation of a “new clinical trials division that will bring innovation and experience together to solve the challenges of recruiting and retaining patients for trials” to provide access to clinical trials in the Improve the communities he serves and create a more efficient and convenient experience to improve participant retention and research effectiveness. “
According to Curebase’s announcement of new funding, the current DCT companies have “focused on narrow parts of the problem, such as the inclusion of wearables,” while aiming to “enable complex studies that can be fully tailored to the patient’s lifestyle” – both at home and at home in real environments.
The company notes that following the COVID-19 pandemic in early 2020, a large number of clinical trials had to be halted, costing some of the largest pharmaceutical companies hundreds of millions in operating and trading losses due to the inability to bring drugs to the market as planned. However, the U.S. Food and Drug Administration issued guidelines in March 2020 that formed the basis for broader roll-out of more patient-centric studies to ensure study continuity. In this environment, Curebase and others want to “make studies not only more patient-oriented, but also faster and cheaper,” explains the company.
There are a dozen clinical trials currently using DCT research methods, according to Curebase, and “research where any patient can log into their home and collect data when they go to their own doctor”. During the pandemic, “six different COVID-19 studies were conducted with community-based pop-up drive-through test sites across the country to turn them into clinical data collection devices with an incredible range of patients,” the company notes.
CVS Health believes that Clinical Trial Services “work with key stakeholders in the biopharmaceutical industry and the entire clinical trial ecosystem to develop and deliver innovative approaches to research and real-world evidence.” The new business will initially focus on:
- Accurate Patient Recruitment – Leverage analytics, national reach, and local community connections to engage individuals by learning about clinical trial opportunities that may be right for them.
- Conduct Clinical Trials – Innovative, decentralized options for conducting Phase III / IV clinical trials and real-world evidence studies at CVS locations, at home or virtually.
- Real Evidence Generation and Studies – Retrospective and prospective studies that measure the effects of novel devices and therapeutics in real world settings.
CVS has also helped the pharmaceutical industry facilitate studies of COVID-19 test treatments and vaccines. The company has already built peer-reviewed articles in clinical research through more than 200 in-home clinical studies, real-world evidence studies, and peer-reviewed publication support, according to CVS. ”
Edited by Gary Cramer